{'fraction_non_alphanumeric': 0.03487179487179487, 'fraction_numerical': 0.03487179487179487, 'mean_word_length': 5.256410256410256, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Low flow nocturnal oxygen therapy does not suppress haemoglobin levels or increase painful crises in sickle cell disease

15 antibodies using the two allelic variants of CD109. Again, the expected immunoreactivity was observed: both antiHPA-15b samples reacted against the HPA-15b variant (CD109, Y682) with little reactivity against HPA-15a (CD109, Y682; Fig 2F, G). Similarly, the two anti-HPA-15a samples showed stronger reactivity to HPA-15a than to HPA-15b (Fig 2H, I); the magnitude of the response again varied between individuals, as expected. Taken together, these data demonstrate that recombinant proteins that contain the epitopes responsible for HPA-5 and HPA-15 alloreactivity can be expressed in a format suitable for systematic screening in a clinical setting. These findings now provide an important proof-of-principle to develop a costeffective screening assay for these HPAs which are responsible for several rare but potentially life-threatening diseases.